Development of novel "patient-tailored DDS"by plasma technique

利用等离子体技术开发新型“患者定制DDS”

基本信息

批准号：
14370730
负责人：
KUZUYA Masayuki
金额：
$ 8.26万
依托单位：
Gifu Pharmaceutical University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (B)
财政年份：
2002
资助国家：
日本
起止时间：
2002 至 2004
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14370730/
关键词：
plasma treatment patient-tailored DDS time-controlled DDS intragastric floating DDS drv orocess crosslinking reaction controlled release oral drug delivery ラグタイム熱効果ガラス転移点

项目摘要

Although oral delivery is convenient to administration and acceptable for patients, the therapeutic effects often depend on the each patient's gastrointenstinal (GI) environment. Therefore, the "Patient-Tailored Drug Delivery System (DDS)" should be developed and administered based on the diagnosis of each patient's GI environment. We have studied plasma-assisted preparation of time-controlled DDS and intragastric floating DDS (FDDS) leading to the "Patient-Tailored DDS" targeting the GI tract. Double-compressed tablets composed of drug tablet as a core material and polymer powder, which was used as pharmaceutical aids, as a wall material was prepared to fabricate time-controlled DDS and inttragastric FDDS.Since plasma-crosslinkable acrylic monomers are one of the component polymers in Eudragits L100-55, argon plasma-irradiation would lead to the suppression of Eudragit L100-55 solubility even in a dissoluble pH-value solution due to the occurrence of the surface cross-link reactions. … More When Eudragit L100-55 is used as a wall material of the double-compressed tablet, the initial drug release could be completely sustained for a certain period of time. The lag-time could be controlled by plasma operational conditions.We have obtained the intragastric FDDS by plasma-irradiation when the double-compressed tablet was prepared using the outer layer to trap evolved carbon dioxide. The double-compressed tablet was prepared using methyl vinyl ether-maleic anhydride copolymer (VEMA), and a mixture of VEMA and hydroxypropyl methylcellulose phthalate as an outer layer. It was found that the tablet plasma-irradiated remains buoyant in the simulated gastric fluids for a prolonged period of time, and the drug release is considerably suppressed. The drug release can be controlled at a desired rate from the tablets by selecting the plasma operational tunings.The present results have clearly shown that one can prepare a variety of desired DDS devices, if one selects the tailored-polymers for wall materials of double-compressed tablets as well as plasma operational conditions. Less

尽管口服输送方便地给药，并且可以接受患者的治疗作用，但治疗作用通常取决于每个患者的胃肠道（GI）环境。因此，应根据每个患者的GI环境的诊断来开发和管理“患者监管药物输送系统（DDS）”。我们已经研究了等离子辅助的时间控制的DDS和胃内浮动DDS（FDD），导致针对GI区域的“患者泰式DDS”。由药品片组成的双重压缩片剂作为核心材料和聚合物粉，用作药物辅助物，作为壁材料的准备，以制造时间控制的DDS和inttragastric FDDS.Sinces plasma-Crosslink-Crosslink-Crosslink-Crosslink-Crosslink Acrylic Acrylic Monomers是Eudagit oudagit oudagit L100-5-5，是eudmir l100-5-5--5---即使在表面交联反应发生的情况下，Eudragit L100-55溶解度即使在可溶解的pH值溶液中。 …更多时，当Eudragit L100-55用作双重压缩片剂的壁材料时，最初的药物释放可以在一定时间内完全维持。滞后时间可以通过血浆操作条件来控制。当使用外层制备双重压缩的片剂以捕获二氧化碳演化的二氧化碳时，我们通过血浆 - 辐射获得了胃内FDD。使用甲基乙烯基螺旋 - 甲基藻共聚物（VEMA）和VEMA和VEMA和羟基丙酰甲基甲磺酸盐的混合物作为外层制备双重压缩片剂。已经发现，片剂血浆辐射的持续时间长时间，并且被认为抑制了药物释放。可以通过选择等离子操作调谐来以片剂的理想速度来控制药物。目前的结果清楚地表明，如果人们为双压缩片剂的墙壁材料选择量身定制的螺栓固定器，以及血浆操作条件。较少的